Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
The interrelationship between cancer and thrombosis is well known. Recent data help physicians to optimize the management of thrombotic complications occurring in cancer patients. However, many issues are still uncertain. First, although the development of venous thromboembolism (VTE) in a patient w...
Saved in:
Main Author: | Sergio Siragusa (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
by: Sergio Siragusa
Published: (2011) -
Primary prevention of venous thromboembolism with low molecular weight heparins in surgical patients - 2024: Council of Experts resolution
by: А. S. Petrikov, et al.
Published: (2024) -
VENOUS THROMBOEMBOLISM IN RELATION TO OVARIAN HYPERSTIMULATION SYNDROME: AN APPROACH TO DETERMINING THE LOW-MOLECULAR-WEIGHT-HEPARIN DOSES AND ACTIVITY
by: I. E. Zazerskaya, et al.
Published: (2016) -
Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
by: Yue Wu, et al.
Published: (2024) -
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
by: Alessandra F. Perna, et al.
Published: (2020)